Telomere Disease¶
Chapter 482 | Part 16: Genes, the Environment, and Disease
KEY CLINICAL POINTS¶
- Telomere attrition is the molecular basis for cellular aging and tissue dysfunction, driven by germline mutations in telomere maintenance genes.
- Dyskeratosis congenita is the classic telomere disease, characterized by short telomeres, bone marrow failure, and multi-organ involvement.
- Telomere length measurement (flow-FISH, qPCR) and next-generation sequencing are critical for diagnosis and genetic counseling.
- Telomere dysfunction increases cancer risk, particularly acute myeloid leukemia and squamous cell carcinomas.
- Long telomeres due to genetic variants predispose to clonal hematopoiesis and malignancies.
1. DEFINITION & OVERVIEW¶
Telomere diseases (telomeropathies) are caused by pathologic accelerated telomere attrition due to germline mutations in telomere maintenance genes. This leads to organ dysfunction from excessive chromosomal end loss, impaired tissue regeneration, and increased cancer risk. Normal aging involves gradual telomere shortening (50 bp/year) without clinical manifestations, whereas telomere diseases result in premature organ failure.
Table 482-1: Genetic Variants in 13 Genes Involved in Telomere Maintenance¶
| GENE | DYSKERATOSI S CONGENITA | APLASTIC ANEMIA | PULMONARY FIBROSIS | CIRRHOSIS | MDS/LEUKEMI A |
|---|---|---|---|---|---|
| Telomerase | |||||
| DKC1 | XL | ||||
| TERT | AD/AR | AD/AR | AD | AD | AD/AR |
| TERC | AD/AR | AD | AD | AD | AD |
| NOP10 | AR | ||||
| NHP2 | AR | ||||
| WRAP53 | AR | ||||
| Shelterin | |||||
| TINF2 | AD | AD | AD | ||
| TERF2 | AD | ||||
| ACD | AD | ||||
| RTEL1 | AR | AD/AR | AD | AD |
| GENE | DYSKERATOSI S CONGENITA | APLASTIC ANEMIA | PULMONARY FIBROSIS | CIRRHOSIS | MDS/LEUKEMI A |
|---|---|---|---|---|---|
| CTC1 | AR | AR | |||
| PARN | AD | ||||
| USB1 | AD | ||||
| ZCCHC8 | AD | AD | |||
| NAF1 | AD |
1.1 Telomere Structure and Function¶
Telomeres are repetitive hexanucleotide sequences (TTAGGG) at chromosome ends, protected by shelterin proteins (TRF1, TRF2, POT1, TIN2, TPP1, RAP1). Telomerase (TERT/TERC) adds GTTAGG repeats to maintain length. Telomere attrition triggers DNA damage response, leading to cell cycle arrest, apoptosis, or chromosomal instability.
1.2 Disease Mechanism¶
Telomere shortening during replication creates 'end-replication problem,' leading to chromosomal erosion. Critically short telomeres activate p53 pathway, causing replicative senescence or apoptosis. Defective telomere repair increases genomic instability and cancer risk.
2. EPIDEMIOLOGY¶
Telomere diseases are rare, with dyskeratosis congenita affecting ~1 in 1 million. Risk factors include inherited telomere defects, environmental exposures (smoking, alcohol, viral infections), and age-related telomere shortening. Organ-specific susceptibility: bone marrow, lungs, liver, and skin show highest vulnerability. Telomere length correlates with lifespan but is not the primary driver of physiological aging.
2.1 Demographics¶
Dyskeratosis congenita typically presents in childhood (first two decades of life). Aplastic anemia and pulmonary fibrosis may occur at any age. Telomere diseases show variable penetrance within families.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Germline mutations in telomere maintenance genes (TERT, TERC, DKC1, RTEL1, etc.) impair telomere elongation. Telomerase dysfunction leads to accelerated attrition in high-proliferation tissues (hematopoietic stem cells, lung epithelium). Defective shelterin proteins (POT1, TRF1) disrupt telomere protection and repair. Environmental factors exacerbate telomere erosion through oxidative stress and inflammation.
3.1 Telomerase Complex¶
Telomerase holoenzyme includes TERT (reverse transcriptase), TERC (RNA template), dyskerin, NHP2, NOP10, and WRAP5, which facilitates telomere elongation. Dyskerin stabilizes the complex and aids telomerase trafficking to Cajal bodies.
4. CLINICAL FEATURES¶
Clinical manifestations vary by organ system. Dyskeratosis congenita presents with mucocutaneous triad (oral leukoplakia, reticular pigmentation, nail dystrophy). Bone marrow failure, pulmonary fibrosis, hepatic cirrhosis, and immunodeficiency are common. Long telomeres may cause clonal hematopoiesis and malignancies.
4.1 Dyskeratosis Congenita¶
Classic presentation includes mucocutaneous triad, bone marrow failure, and organ-specific complications. Telomeres are <1st percentile for age. 20% develop pulmonary fibrosis, 10% liver disease.
4.2 Pulmonary Fibrosis¶
Occurs in ~20% of dyskeratosis congenita patients. Idiopathic pulmonary fibrosis patients with telomere defects may have cryptic cirrhosis. Histopathology shows interstitial pneumonia and honeycomb lung architecture.
5. DIFFERENTIAL DIAGNOSIS¶
Distinguish telomere diseases from acquired aplastic anemia, myelodysplastic syndromes, and idiopathic pulmonary fibrosis. Family history of telomere defects, leukocyte telomere length testing, and genetic screening are critical for differentiation.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis relies on telomere length measurement (flow-FISH, qPCR) and genetic testing. Leukocyte telomere length <10th percentile suggests telomere disease. Next-generation sequencing identifies mutations in TERT, TERC, DKC1, RTEL1, etc. Telomere length is a top predictor in machine-learning tools for bone marrow failure syndromes.
6.1 Telomere Length Measurement¶
Flow-FISH measures individual cell telomere length; qPCR estimates average telomere length. Normal ranges vary by age (longest at birth, shortening 40–60 bp/year). Telomeres >99th percentile indicate long telomere syndrome.
7. MANAGEMENT & TREATMENT¶
Management includes hematopoietic stem cell transplantation for marrow failure, antifibrotic therapies for pulmonary fibrosis, and liver transplantation for cirrhosis. Telomere length monitoring and genetic counseling are essential. No curative treatment exists for telomere defects.
7.1 Bone Marrow Failure¶
Transfusion support and HSCT are mainstays. Patients with aplastic anemia and telomere defects require close monitoring for myelodysplastic syndromes.
8. PROGNOSIS & COMPLICATIONS¶
Telomere diseases have poor prognosis due to multi-organ failure and increased cancer risk. Complications include pulmonary fibrosis, hepatic cirrhosis, and myeloid neoplasms. Long telomeres increase clonal hematopoiesis and malignancy risk.
8.1 Cancer Risk¶
Telomere dysfunction increases risk of acute myeloid leukemia, head and neck squamous cell carcinoma, and hepatocellular carcinoma. Murine models show telomerase deficiency accelerates tumorigenesis.
9. SPECIAL CONSIDERATIONS¶
Pregnancy and pediatric populations require careful monitoring due to telomere-related complications. Elderly patients with telomere defects face higher risks of organ failure. Environmental factors (smoking, alcohol) exacerbate telomere erosion.
10. KEY POINTS & CLINICAL PEARLS¶
- Telomere attrition is the molecular basis for aging and tissue dysfunction.
- Dyskeratosis congenita is the prototypical telomere disease with multi-organ involvement.
- Telomere length measurement and genetic testing are critical for diagnosis.
- Telomere defects increase cancer risk and require lifelong monitoring.
- Environmental factors accelerate telomere erosion in susceptible individuals.